A study has demonstrated that the combination of PD-1 inhibitors with anti-VEGF-targeted drugs shows better therapeutic effects than monotherapy in the systemic treatment of patients with advanced HCC [8]. Here, VEGFA is linked to hepatocellular carcinoma.